Beigene Stock

Beigene FCF Yield

Delisted·Jun 18, 2026

The Free Cash Flow Yield of Beigene (6160.HK) as of Aug 12, 2026 is 5.57 %. In the previous year, Free Cash Flow Yield was -3.86 % — a change of -244.50% (higher).

FCF Yield

5.57 %

YoY

-244.50%

Last updated:

Free Cash Flow Yield of Beigene is 2026 5.57 % . Free Cash Flow Yield of Beigene was 2025 -3.86 % . It decreases by -244.50% higher compared to the previous year.
Access this data via the Eulerpool API

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beigene stock

Free Cash Flow Yield of Beigene is 5.57 % in 2026.

Free Cash Flow Yield of Beigene changed from -3.86 % to 5.57 %, representing a -244.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Beigene since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Beigene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Beigene

All Key Metrics — Beigene